LEMAITRE VASCULAR INC (LMAT) Form 10-Q — Aug 5, 2026
LeMaitre Vascular reported Q2 2026 net sales of $70.4 million, up 10% year over year, driven by higher average selling prices, higher unit volumes, and the European launch of Artegraft. Six-month sales rose 10% to $136.9 million. Net income grew 24% to $17.1 million with diluted EPS of $0.74 versus $0.60 a year ago, as gross margin expanded 210 basis points to 72.1% on price increases, favorable product mix, and lower shipping costs. The balance sheet shows $26.6 million of cash plus $349.6 million in short-term marketable securities against $172.5 million of 2.50% convertible notes due 2030, which are now dilutive (1.4M shares added to the diluted count).
Key figures
- Eps
- 0.74
- Revenue
- 70382000
- Net Income
- 17050000
- Total Debt
- 172500000
- Revenue Yoy
- 10%
- Cash Position
- 26625000
- Shares Outstanding
- 22869257
- Gross Margin Q2
- 72.1% (vs 70.0% prior year, +210bps)
- Six Month Revenue
- 136933000
- Buyback Used To Date
- none
- Six Month Net Income
- 32729000
- Effective Tax Rate Q2
- 23.2%
- Six Month Diluted Eps
- 1.42
- Sales Force Headcount
- 163
- Buyback Authorization Usd
- 100000000
- Convertible Notes Maturity
- February 1, 2030
- Operating Income Six Months
- 38174000
- Convertible Notes Fair Value
- 183300000
- Convertible Notes Principal
- 172500000
- Dividend Per Share Quarterly
- 0.25
- Convertible Notes Interest Rate
- 2.50%
- Convertible Notes Carrying Value
- 169091000
- Short Term Marketable Securities
- 349615000
- Net Cash From Operations Six Months
- 31058000
Price after filing
Close on the filing date to close N calendar days later (from $103.61). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.